SVSvetlana V. Villevalde

Svetlana V. Villevalde

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Svetlana V. Villevalde has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Results of a prospective, observational, multicenter study of patients with hypertension and chronic kidney disease in the Russian Federation (PRIORITY-CKD)

    by E. V. Shlyakhto, G. P. Arutyunov, M. M. Batyushin, S. V. Villevalde, N. E. Zvartau, S. V. Nedogoda, E. M. Shilov, A. E. Soloveva, E. A. Medvedeva, E. A. Zorina, et al.

    Aim. To assess the incidence of chronic kidney disease (CKD) in adult patients with hypertension (HTN) and markers of CKD without concomitant diabetes and symptomatic heart failure, as well as to describe the clinical and demographic characte­ristics and treatment options in the overall cohort and a subgroup with verified CKD. Material and methods. PRIORITY-CKD is a multicenter, observational, prospective study with a retrospective analysis of patients with hypertension and markers of CKD in the Russian Federation. The study design has been described in detail previously. Results. The analytical cohort included 9914 patients. The diagnosis of CKD was confirmed in 8430 (85%) patients with HTN and CKD markers during the study as follows: 3795 (38,3%) at Visit 1 and 4635 (46,8%) at Visit 2. The estimated glomerular filtration rate was used as diagnostic criteria in 8406 (97,4%) cases. Albuminuria/proteinuria and a combination of markers were used in 13 (0,2%) and 11 (0,1%) patients, respectively. In the overall cohort and the subgroup with verified CKD, women predominated, the median duration of hypertension was similar and amounted to 10 years. More than half of the patients had stage III hypertension and the very high cardiovascular risk ca­tegory. A high frequency of metabolic risk factors (overweight, abdominal obesity, dyslipidemia) and coronary artery disease (33%/34,9% in the two cohorts, respectively) was observed. Uncontrolled blood pressure (BP) (systolic BP ≥140 and/or diastolic BP ≥90 mm Hg while receiving antihypertensive therapy (AHT)) and signs of AHT resistance were detected in 36,0% and 6,0% of patients in the overall cohort, respectively, and in the same proportion of patients in the CKD subgroup. Combination AHT was received by 72,3% of patients in the study cohort after Visit 1. After CKD diagnosis was confirmed, sodium-glucose cotransporter type 2 inhibitors were prescribed in 31,1% of cases. Conclusion. In the Russian population, CKD was confirmed in 85% of patients with HTN and CKD markers. Albuminuria/proteinuria was assessed extremely rarely. A high frequency of uncontrolled HTN, a significant burden of metabolic risk factors, and cardiovascular disease were observed in the overall cohort and the CKD subgroup. The incremental use of renoprotective therapy after verification of the CKD diagnosis was insufficient.

  • Open Access

    Evolution of the concept of metabolic syndrome and its place in the International Classification of Diseases

    by E. V. Shlyakhto, S. V. Nedogoda, N. E. Zvartau, S. V. Villevalde, E. A. Medvedeva, E. I. Usova, Е. В. Шляхто, С. В. Недогода, Н. Э. Звартау, С. В. Виллевальде, et al.

    The evolving understanding of metabolic syndrome (MS) as a multiorgan clinical and pathophysiological continuum conflicts with the prevailing principles of its statistical evaluation, which are based primarily on the isolated coding of indivi­dual components. This article analyzes the transformation of approaches to meta­bolic syndrome coding in various versions of the International Classification of Diseases and rela­ted health problems from the perspective of modern concepts of cardiovascular-renal-metabolic and cardiovascular-renal-hepatic-metabolic syndromes. The presented prospects for the implementation of independent coding of metabolic syndrome reflect not a change in nosological status, but rather the natural evolution of classification systems in the context of the development of patient-centered healthcare models.

  • Open Access

    Consensus Interdisciplinary Positions of the Metabolic Syndrome Supervisory Committee

    by E. V. Shlyakhto, G. P. Arutyunov, A. Yu. Babenko, S. A. Boytsov, S. V. Villevalde, I. I. Dedov, O. M. Drapkina, S. O. Eliashevich, N. E. Zvartau, V. T. Ivashkin, et al.

    Consensus Interdisciplinary Positions of the Metabolic Syndrome Supervisory Committee | Shlyakhto | Russian Journal of Cardiology Согласительные междисциплинарные позиции наблюдательного комитета по метаболическому синдрому | Шляхто | Российский кардиологический журнал


  • Open Access

    Metabolic Syndrome: A Registry Study of Patients in the Russian Federation (METEOR). Rationale, objectives, design, and methodology

    by E. V. Shlyakhto, N. E. Zvartau, S. V. Villevalde, S. V. Nedogoda, E. A. Medvedeva, E. I. Usova, V. A. Karlina, M. V. Dubinina, Е. В. Шляхто, Н. Э. Звартау, et al.

    This paper presents the rationale, design, and methodology of the prospective, observational, multicenter study "Metabolic Syndrome: A Registry Study of Patients in the Russian Federation (METEOR)". The are following study aims: to describe the clinical and demographic characteristics, diagnostic methods, and treatment options used in outpatients with metabolic syndrome (MS) in a real-world clinical practice; to evaluate baseline characteristics and progression across MS stages within various phenotypes; and to identify factors associated with clinical outcomes during the follow-up period in the general patient population and in subgroups of interest. The study will sequentially enroll all adult outpatients with MS who are followed up by a general practitioner, primary care physician, and/or specialized professionals, who have signed an informed consent, and who meet the inclusion criteria. Data will be collected on a single digital platform in the patient’s electronic individual case report form. The follow-up period begins on the day of Visit 1, with Visit 2 occurring 6 months (±3 months) after Visit 1. Visit 3 and subsequent visits will be conducted 12 months (±3 months) after Visit 1, and then annually thereafter collect information on the patient’s clinical status and endpoints.

  • Open Access

    Prevalence, clinical, and prognostic role of metabolic syndrome in patients with heart failure: A subanalysis of the PRIORITY-HF study

    by E. V. Shlyakhto, Yu. N. Belenkov, S. A. Boytsov, S. V. Villevalde, A. S. Galyavich, M. G. Glezer, N. E. Zvartau, Zh. D. Kobalava, Yu. M. Lopatin, V. Yu. Mareev, et al.

    Aim. To assess the prevalence of individual components of metabolic syndrome (MS), the incidence of MS, and its clinical and prognostic significance in outpatients with heart failure (HF). Material and methods. This retrospective analysis of data from the PRIORITY-HF multicenter registry study of patients with HF in the Russian Federation was conducted. The analytical cohort included 19939 patients, and the primary and se­condary criteria of MS were analyzed. A group with MS was identified according to diagnostic criteria, and combinations of components were assessed. In addition, cluster analysis was performed, and prognosis was evaluated. Results. In the analyzed cohort, the primary criteria of MS were identified with high frequency as follows: obesity in 45,6%, HTN in 89%, and type 2 diabetes in 27,4% of patients. Among the additional criteria, the highest prevalence was observed for dyslipidemia/lipid-lowering therapy in 80,7%, impaired renal function/damage in 62%, and hyperuricemia/urate-lowering therapy in only 5% of patients. MS was diagnosed in 14403 (70,4%) patients. Among patients with MS, the following distribution was noted depending on the burden of main criteria: 48,8% — 2, 28% — 1, and 23,2% — 3 main criteria. The most frequent combination was HTN + dyslipidemia/lipid-lowering therapy + impaired renal function/damage both in the overall cohort with MS and in the subgroups by left ventricular ejection fraction. Patients with HF with preserved ejection fraction, compared with other phenotypes, had a higher frequency of combinations with 3 main criteria in the composition. Patients with metabolic syndrome (MS) had a significantly higher risk of hospita­lization for cardiovascular causes (odds ratio 1,142, 95% confidence interval 1,033-1,263) than patients without MS (p=0,01). Among the identified MS clusters, cluster 1 was characterized by older patient age, a greater burden of kidney impairment/da­mage, and the poorest prognosis. Conclusion. A high prevalence of individual MS components was found among patients with heart failure. MS was diagnosed in 70,4% of cases. The broad profile of the obtained combinations of MS components reflects the diversity of me­tabolic disorders in HF patients. MS was associated with a significantly increased risk of hospitalization for cardiovascular causes compared to patients without MS. Cluster analysis demonstrated heterogeneity of patients with MS in clinical cha­racteristics and prognosis.

  • Open Access

    Role of Steroidal Mineralocorticoid Receptor Antagonists in the Treatment of Patients with Heart Failure with a Left Ventricular Ejection Fraction ≤40%. Expert council resolution

    by G. P. Arutyunov, A. S. Galyavich, S. N. Tereshchenko, F. T. Ageyev, O. L. Barbarash, S. V. Villevalde, I. V. Zhirov, N. A. Koziolova, Yu. M. Lopatin, S. V. Nedogoda, et al.

    Mineralocorticoid receptor antagonists are currently considered as a standard therapy for patients with heart failure with a reduced left ventricular ejection fraction. This drug group includes agents with different efficacy and safety profiles. The expert council’s resolution addresses the differentiated use of mineralocorticoid receptor antagonists in the treatment of patients with heart failure with a left ventricular ejection fraction ≤40%.

  • Open Access

    Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG

    by E. V. Shlyakhto, I. I. Dedov, V. N. Serov, G. T. Sukhikh, G. P. Arutyunov, I. A. Suchkov, O. M. Drapkina, O. N. Tkacheva, Ya. A. Orlova, I. I. Baranov, et al.

    Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice

  • Prospects for finerenone use in heart failure with a left ventricular ejection fraction ≥40%: value of the results of the FINEARTS-HF phase III randomized clinical trial (expert panel summary)

    by Yu. M. Lopatin, S. N. Tereshchenko, G. P. Arutyunov, S. V. Villevalde, A. S. Galyavich, D. V. Duplyakov, I. V. Zhirov, N. E. Zvartau, O. B. Irtyuga, N. A. Koziolova, et al.

    Heart failure with mildly reduced and preserved ejection fraction is a serious problem in modern healthcare due to its high prevalence, unfavorable prognosis, and significant limitations in optimal therapy. This article represents the re­solution of an expert panel devoted to the prospects for finerenone use in heart failure with a left ventricular ejection fraction ≥40%, based on the results of the FINEARTS-HF phase III randomized clinical trial. The data obtained demonstrate a high efficacy and safety profile for finerenone in this patient group, which rationales including this drug in widespread clinical practice for the treatment of sym­ptomatic heart failure with a left ventricular ejection fraction ≥40% after registration of the appropriate indication.

  • Open Access

    Menopausal hormone therapy in patients with cardiovascular and metabolic diseases: an interdisciplinary Delphi consensus among Russian gynecologists, cardiologists, endocrinologists, gerontologists and geriatricians, phlebologists, and clinical pharmacologists

    by Gennadii T. Sukhikh, Vladimir N. Serov, Evgeny V. Shlyakhto, Ivan I. Dedov, Gregory P. Arutyunov, Olga N. Tkacheva, Antonina A. Smetnik, Igor A. Suchkov, Igor I. Baranov, Marina V. Shestakova, et al.

    More than one million women in Russia enter menopause each year. The severe estrogen deficiency associated with this transition causes symptoms that significantly impair quality of life and contribute to an increased risk of cardiovascular and metabolic diseases. Menopausal hormone therapy (MHT) is the established standard of care for menopausal symptoms. On the initiative of several professional societies (the Russian Society of Obstetricians and Gynecologists, the Russian Society of Cardiology, the Russian Association of Endocrinologists, the Eurasian Association of Therapists, the Russian Society of Gynecological Endocrinology and Menopause, the Russian Association of Gerontologists and Geriatricians, the Association of Phlebologists of Russia), a Delphi panel was convened to develop a multidisciplinary expert consensus on MHT for patients with cardiovascular and metabolic diseases. The goal was to enhance research and clinical approaches to managing menopausal women. A consensus was reached at the end of the first Delphi round. The experts agreed that initiating MHT requires a thorough assessment of individual risks, including cardiovascular health and comorbidities. MHT can offset metabolic and cardiovascular risk factors in peri- and postmenopausal women by normalizing the lipid profile, improving carbohydrate metabolism, and reducing insulin resistance. An interdisciplinary approach allows for personalized MHT, minimizes potential complications, improves the quality of life for peri- and postmenopausal women, and promotes active longevity.


  • Cost‑effectiveness analysis of a specialized heart failure patient management system at the regional level

    by S. V. Nedogoda, N. E. Zvartau, A. E. Solovyova, S. V. Villevalde, A. S. Salasyuk, S. L. Bolotova

    Aim . To conduct a cost-effectiveness analysis of implementing a specialized heart failure (HF) patient management system at the regional level. Material and methods . The necessary costs for implementing a specialized HF patient management system in average region within the current healthcare system included staff salaries, training costs, and equipment costs for outpatient HF clinics, inpatient HF departments, and HF patient "schools". To assess the potential economic impact of implementing a specialized HF management system in the region, a mathematical HF model was proposed. This model assumed (1) the absence of such a system in the region, (2) current treatment consistent with the PRIORITY-HF study data, and (3) achievement of optimal HF therapy (a combination of an angiotensin receptor-neprilysin inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, and a sodium-glucose cotransporter-2 inhibitor) in all patients based on the implementation of the specialized heart failure management system. The potential HF population in the region was calculated per 100 000 residents. Results . Taking into account standards for cardiologist workload and HF prevalence, one outpatient HF center/office for every 400 000 residents should be established. The amount of additional funding required to expand the implementation of specialized HF patient management systems per 100 000 people (based on the costs of equipment, salaries, and training in the first year and salaries in subsequent years) is RUB 1,6 million for the first year, RUB 4,3 million over 3 years, and RUB 13,7 million over the 10-year analysis (i.e., an average of RUB 1,4 million per year). We demonstrated that, by improving the efficiency of patient management, specialized heart failure patient monitoring systems become economically feasible already within the first year of implementation. The overall reduction in budget expenditures, taking into account the costs of implementing specialized HF patient management systems, amounted to RUB 5,5 million, or RUB -3,128 per 1 HF patient subject to monitoring. Moreover, over 10 years of implementation, 827 deaths and 678 hospitalizations due to heart failure will be prevented per 100 000 people, while budget savings (taking into account cost savings on hospitalizations and deaths in patients with HF with a lower probability of disease progression) will amount to RUB 5,5 million in the first year, RUB 13,9 million over 3 years, and RUB 22,9 million over 10 years over the analysis. Conclusion . The implementation of specialized HF patient management systems may represent an optimal strategy for reducing the burden of disease both in terms of the clinical effectiveness of treatment and economic feasibility.